

Supplementary Information for

Fuscoside Attenuates Bone Loss in Bone Defects by Regulating The Rankl/Nlrp3/Opg Pathway in Rats

Xiangwei Liu, M.D., Binfeng Wang, M.D.*

Department of Traumatic Orthopedics, Chifeng Municipal Hospital, Chifeng, Inner Mongolia, China

*Corresponding Address: Department of Traumatic Orthopedics, Chifeng Municipal Hospital, Chifeng, Inner Mongolia, China
Email: wangbinfeng1258@qq.com

Table S1: Gene sequence of primers

Sr. No.	Gene	Primer sequence (5'-3')
1	<i>Rankl</i>	F: CCGTGCAAAGGGAATTACAAC R: GAGCCACGAACCTTCCATCA
2	<i>Nlrp3</i>	F: GGACTGAAGCACCTGTTGTGCA R: TCCTGAGTCTCCCAAGGCATTC
3	<i>Opg</i>	F: GGAGACACAGCTCGCAAGA R: GCACACTGCTTTTACAGAGG
4	<i>Runx2</i>	F: TCACAAATCCTCCCCAAGTGG R: GAATGCGCCCTAAATCACTGA
5	<i>Osterix</i>	F: GCTTTTCTGTGGCAAGAGGTTC R: CTGATGTTTGCTCAAGTGGTCC
6	<i>Oc</i>	F: GCTGGCCCTGACTGCATTCTG R: ATCACCACCTTACTGCCCTCCTG
7	<i>β-Actin</i>	F: CACCATTGGCAATGAGCGGTTC R: AGGTCTTTGCGGATGTCCACGT

Table S2: Influence of fuscoside on serum biochemical markers in bone defect rats

Group	OC (pg/mL)	CTX (ng/mL)	BSAP (U/L)
Sham	9.47 ± 0.37	32.73 ± 3.18	6.18 ± 0.27
BD	2.93 ± 0.28 ^{##}	152.9 ± 8.06 ^{##}	15.33 ± 0.63 ^{##}
Fuscoside 200 mg/kg	5.61 ± 0.51 ^{**}	106.73 ± 5.39 ^{**}	12.15 ± 0.41 ^{**}
Fuscoside 300 mg/kg	7.84 ± 0.47 ^{**}	61.29 ± 2.74 ^{**}	8.72 ± 0.25 ^{**}

Data are presented as mean ± SEM (n=8). BD; Bone defect group, OC; Osteocalcin, CTX; C-terminal telopeptide of type 1 collagen, BSAP; Bone specific alkaline phosphatase, ^{##}; P<0.01 vs. sham-operated group, and ^{**}; P<0.01 vs. BD group.